=Meridian Bioscience (VIVO) reported earnings on Thur 27 July 2017 (b/o)

Meridian Bioscience misses by $0.01, beats on revs; reaffirms FY17 EPS guidance, revs guidance :

• Reports Q3 (Jun) earnings of $0.16 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.17; revenues fell 1.0% year/year to $50.14 mln vs the $49.13 mln Capital IQ Consensus.
• Co reaffirms guidance for FY17, sees EPS of $0.64-0.69, excluding non-recurring items, vs. $0.68 Capital IQ Consensus Estimate; sees FY17 revs of $193-199 mln vs. $197.6 mln Capital IQ Consensus Estimate.
• "Our overall business continued to stabilize, with [JunQ] revenue declining 1% (flat on a constant currency basis), reflecting continued strong performance from both of our Life Science units, largely offset by modest declines in our Diagnostics segment. Our Life Science segment revenues grew 8% (10% in constant currency), while the Diagnostics segment declined 4% (also 4% in constant currency)."